Novo Nordisk faces scrutiny over UK pharmacy sponsorships tied to weight-loss drugs, with critics citing conflicts of interest and regulatory breaches.

Claiming Science magazine's breakthrough of the year in 2023 , these drugs are an absolute revelation: they give you long-lasting weight loss as long as you continue taking them .

The anti-obesity drug Zepbound made by Eli Lilly & Co. could be one of the biggest cost drivers for health insurers and ...

Novo Nordisk petitions the FDA to exclude liraglutide from the 503B Bulks List, citing safety risks, lack of clinical need, ...

In a citizen petition posted by the FDA this week, Novo urged the regulator to restrict the ability of compounding pharmacies ...

Experts recommend 5 peptide-based medications for weight loss, such as liraglutide and semaglutide. They require medical ...

Experimental weight-loss drug Retatrutide shows promise, helping obese adults lose up to 22% of their weight in 48 weeks.

The FDA rejected sotagliflozin (Zynquista) as an adjunct to insulin therapy for glycemic control in adults with type 1 ...

Novo Nordisk (NOVO) is petitioning the FDA to exclude its diabetes drug liraglutide, also known as Victoza, from a list of ...

leading to weight loss. Liraglutide, which mimics GLP-1, was released in 2010 as Victoza, a diabetes treatment, and ...

Right now, Novo stock is trading at a forward price-to-earnings (P/E) multiple of 22.5 -- its lowest level in well over a ...